1. Pharmacokinetics & Absorption Dynamics

Conventional oral iron salts (ferrous sulfate/fumarate) release reactive Fe2+ ions in the stomach, generating mucosal oxidative hydroxyl radicals and provoking gastric distress. Liposomal technology encapsulates elemental iron inside spherical lecithin-phospholipid bilayers mimicking natural cell membranes. This shields iron molecules from gastric acid denaturation and facilitates intact transcytosis across microvillous intestinal M-cells and enterocytes via clathrin-dependent endocytosis, releasing elemental iron directly into systemic macrophage reticuloendothelial storage depots.

2. Biological Mechanism of Action (MOA)

totally preventing gastric irritation and metallic taste.

higher biological bioavailability.

without sparking systemic hepcidin resistance.

• 1. Eliminates Gastric Mucosal Contact: Bypasses stomach enterocyte DMT1 (Divalent Metal Transporter 1) saturable pathways,
• 2. Enhanced Reticuloendothelial Uptake: Promotes endocytosis directly into lymphatic mesenteric systems, ensuring up to 3.5x
• 3. Direct Ferritin Replenishment: Transports iron safely to liver and bone marrow erythroblasts for efficient heme incorporation

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Hb Elevation: +2.1 g/dL over 12 weeks with only 30 mg elemental iron
• Ferritin Augmentation: +312% baseline increase in tissue storage
• Adverse GI Events: 91% reduction vs conventional iron salts (p < 0.0001)
• Compliance Rate: >98% patient completion without gastrointestinal distress

5. Safety & Regulatory Alignment

GRAS affirmed, WHO-GMP certified, FSSAI Schedule IV nutraceutical compliant. Free of heavy metals, non-GMO, and formulated in alignment with ICMR-NIN DRI 2020 recommendations.

6. Key References (PubMed / Academic)

[1] Pisani A, et al. Effects of oral liposomal iron versus intravenous iron in CKD patients. Blood Transfus. 2015;13(3):397-404.

[2] Parisi F, et al. Effects of highly bioavailable liposomal iron in pregnant women. J Matern Fetal Neonatal Med. 2017;30(15):1787-1792.

[3] Tolkien Z, et al. Ferrous sulfate supplementation causes significant GI adverse events: systematic review and meta-analysis. PLoS One. 2015;10(2):e0117383.

1. Pharmacokinetics & Absorption Dynamics

Ascorbic acid is a water-soluble electron donor that rapidly reduces insoluble ferric iron (Fe3+) into the soluble ferrous (Fe2+) state within the duodenal lumen. Simultaneously, it forms low-molecular-weight stable soluble chelates that withstand the neutral pH of the upper duodenum, rendering iron accessible to enterocyte apical membrane transporters.

2. Biological Mechanism of Action (MOA)

intestine.

inhibiting bacterial proliferation.

• 1. Redox Potentiation: Converts dietary and supplementary trivalent iron into bivalent form for active DMT1 uptake.
• 2. Overcomes Dietary Inhibitors: Blocks the binding of polyphenols, tannins, and phytates that otherwise precipitate iron in the
• 3. Urothelial Defense: In urinary pathways, high urinary excretion of ascorbate creates an unfavorable low pH environment

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Fractional Iron Uptake: Increased from 2.8% to 8.4% (3-fold increase)
• Inhibitor Neutralization: 100% reversal of polyphenol-induced chelation resistance
• Safety Index: Well-tolerated at physiological therapeutic dosages under upper tolerable limits

5. Safety & Regulatory Alignment

Meets USP/FCC monographs, ICMR DRI 2020 aligned, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Hallberg L, et al. Iron absorption in man: ascorbic acid and dose-dependent stimulation. Am J Clin Nutr. 1989;49(1):140-144.

[2] Lynch SR, Cook JD. Interaction of vitamin C and iron. Ann N Y Acad Sci. 1980;355:32-44.

[3] Carr AC, Maggini S. Vitamin C and Immune Function. Nutrients. 2017;9(11):1211.

1. Pharmacokinetics & Absorption Dynamics

Unlike cyanocobalamin which requires hepatic metabolic decyanation and enzymatic conversion, methylcobalamin is the direct coenzyme form active in human cytoplasm. It serves as a necessary methyl group donor for methionine synthase, catalyzing the conversion of homocysteine into methionine, an essential precursor for S-adenosylmethionine (SAMe) and myelin sheath synthesis.

2. Biological Mechanism of Action (MOA)

normoblastic red cell development.

• 1. Erythropoiesis Support: Regulates purine and thymidylate synthesis indispensable for cellular DNA maturation during
• 2. Homocysteine Clearance: Lowers cardiotoxic and endothelial-damaging homocysteine concentrations.
• 3. Neuro-Protection: Enhances peripheral nerve axonal regeneration and prevents subacute combined spinal degeneration.

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• MCV Normalization: Red blood cell volume returned to 86-92 fL within 3 weeks
• Homocysteine Reduction: 38% decrease in plasma homocysteine levels
• Fatigue Index: Statistically significant reduction in clinical fatigue scores (p < 0.01)

5. Safety & Regulatory Alignment

Zero recognized toxicity even at high oral intakes; complies with FSSAI regulations and WHO guidelines.

6. Key References (PubMed / Academic)

[1] Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149-160.

[2] Green R, et al. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017;3:17040.

1. Pharmacokinetics & Absorption Dynamics

Conventional synthetic folic acid requires multi-step reduction by Dihydrofolate Reductase (DHFR) and Methylenetetrahydrofolate Reductase (MTHFR). In approximately 40-50% of the population carrying MTHFR C677T or A1298C polymorphisms, this conversion is severely impaired, leading to circulating toxic unmetabolized folic acid (UMFA). L-Methylfolate directly enters cellular circulation without metabolic bottleneck.

2. Biological Mechanism of Action (MOA)

proliferation.

• 1. Direct Cellular Utilization: Serves as immediate methyl donor for remethylation of homocysteine to methionine.
• 2. Bypasses MTHFR Mutations: Provides 100% biological availability independent of MTHFR genotype.
• 3. DNA Synthesis & Repair: Vital for purine and pyrimidine biosynthesis during fetal embryogenesis and maternal tissue

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• RBC Folate Saturation: Reached protective threshold (>906 nmol/L) within 4 weeks
• Plasma UMFA: 0% detectable circulating synthetic folic acid
• MTHFR Mutation Resilience: Uniform therapeutic efficacy in homozygous TT variants

5. Safety & Regulatory Alignment

US FDA NDI accepted, EFSA approved, FSSAI approved as active folate source.

6. Key References (PubMed / Academic)

[1] Lamers Y, et al. Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally increases red blood cell folate. Am J Clin Nutr. 2006;84(1):156-161.

[2] Pietrzik K, et al. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics. Clin Pharmacokinet. 2010;49(8):535-548.

1. Pharmacokinetics & Absorption Dynamics

Standard inorganic zinc salts (zinc sulfate/oxide) dissociate in the stomach, yielding astringent free zinc ions that irritate gastric walls and compete with iron for DMT1 enterocyte transport. In Zinc Bisglycinate, the zinc atom is covalently bound between two glycine molecules, creating an electrically neutral, stable heterocyclic ring structure that passes through the pylorus intact and absorbs via peptide transporters (PEPT1).

2. Biological Mechanism of Action (MOA)

with iron.

• 1. Non-Competitive Absorption: Bypasses shared iron-zinc divalent transporter antagonism, allowing simultaneous absorption
• 2. SOD Cofactor: Essential component of Copper-Zinc Superoxide Dismutase (Cu/Zn-SOD), neutralizing superoxides.
• 3. Epithelial Repair: Promotes collagen synthesis, RNA polymerase transcription, and mucosal integrity.

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Bioavailability: +43.4% greater systemic plasma AUC vs gluconate
• Gastric Tolerance: 100% tolerance without nausea or emetic episodes
• Anti-Inflammatory Index: 34% reduction in systemic inflammatory markers

5. Safety & Regulatory Alignment

GRAS certified, ICMR DRI 2020 compliant, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Gandia P, et al. A bioavailability study comparing two oral formulations containing zinc. Int J Vitam Nutr Res. 2007;77(4):243-248.

[2] Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol Med. 2008;14(5-6):353-357.

1. Pharmacokinetics & Absorption Dynamics

A-type proanthocyanidins contain specific double interflavanoid linkages (unlike the B-type found in apples or cocoa). Following oral ingestion and partial colonic microbial breakdown, active metabolites and intact PAC oligomers filter into urine via renal clearance, achieving high anti-adhesion concentration in the bladder within 2 hours.

2. Biological Mechanism of Action (MOA)

preventing bacterial pili from anchoring to uroplakin receptors on urothelial cells.

• 1. Anti-Adhesion Mechanism: Binds to Gal(a1-4)Galb receptor targets on P-fimbriated Uropathogenic Escherichia coli (UPEC),
• 2. Non-Bactericidal Action: Prevents bacterial colonization without applying antibiotic selective pressure, avoiding drug resistance.
• 3. Uropathogen Clearance: Entrains unanchored bacteria to be eliminated naturally through physiological urinary voiding.

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Recurrent UTI Reduction: 54% reduction in confirmed clinical episodes (Cochrane verified)
• Duration of Action: Urothelial anti-adherence lasts 24 hours at 36 mg PAC threshold
• Antibiotic Sparing: 68% decrease in clinical antibiotic requirement

5. Safety & Regulatory Alignment

Well-established safety profile, non-antibiotic preventive agent, FSSAI approved botanical.

6. Key References (PubMed / Academic)

[1] Williams G, et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;4:CD001321.

[2] Howell AB, et al. Dosage effect on uropathogenic E. coli anti-adhesion activity in urine following consumption of cranberry powder. BMC Infect Dis. 2010;10:94.

1. Pharmacokinetics & Absorption Dynamics

D-mannose is a naturally occurring aldohexose sugar that is poorly metabolized in humans. Approximately 90% of an ingested oral dose is rapidly absorbed from the upper gastrointestinal tract into the bloodstream without altering systemic blood glucose levels, filtering unchanged through the renal glomeruli into the urinary bladder within 30 to 60 minutes.

2. Biological Mechanism of Action (MOA)

the tips of bacterial type 1 fimbriae.

glycoproteins.

vaginal lactobacilli.

• 1. FimH Competitive Saturation: Possesses high-affinity stereochemical complementarity to the FimH adhesin protein localized at
• 2. Bacterial Ensnarement: Saturates FimH binding pockets before bacteria can latch onto urothelial cell mannosylated
• 3. Flushes Pathogens Intact: Traps free-floating bacteria in urine, allowing effortless expulsion during micturition without disturbing

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Recurrence Rate: Dropped from 60.8% to 14.6% (identical efficacy to antibiotics)
• Safety Profile: 4x fewer adverse events than daily antibiotic prophylaxis
• Glycemic Neutrality: Zero impact on fasting blood glucose or HbA1c in diabetic women

5. Safety & Regulatory Alignment

GRAS affirmed, safe for long-term daily prophylactic usage, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Kranjcec B, et al. D-mannose powder for prophylaxis of recurrent urinary tract infections in adult women: a randomized clinical trial. World J Urol. 2014;32(1):79-84.

[2] Altarac S, Papes D. Use of d-mannose in prophylaxis of recurrent urinary tract infections. BJU Int. 2014;113(1):9-10.

1. Pharmacokinetics & Absorption Dynamics

The calyx of Hibiscus sabdariffa is rich in organic hibiscus acid, protocatechuic acid, and anthocyanins (delphinidin-3-sambubioside). Following oral administration, these active flavonoids undergo swift intestinal transit and conjugate into glucuronides that reach the renal tubules, producing a gentle physiological aquaretic (diuretic) flushing action without electrolyte depletion.

2. Biological Mechanism of Action (MOA)

• 1. Multi-Pathogen Antimicrobial Action: Exhibits strong bacteriostatic and antifungal activity against E. coli and Candida albicans.
• 2. Biofilm Disruption: Disrupts extracellular polysaccharide matrix biofilms in chronic recurrent urothelial reservoirs.
• 3. Urothelial Spasmolysis: Relieves smooth muscle bladder spasms, reducing painful urinary urgency and dysuria.

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• UTI Episode Reduction: 77% clinical reduction over 24 weeks
• Symptom Relief: 68% faster relief of dysuria and bladder burning
• Antifungal Synergy: Proven inhibition against Candida albicans co-infections

5. Safety & Regulatory Alignment

Traditional botanical with established safety, FSSAI approved, WHO-GMP certified.

6. Key References (PubMed / Academic)

[1] Allaert FA. Prevention of urinary tract infections: a double-blind, randomized, placebo-controlled study with Hibiscus sabdariffa. Phytomedicine. 2009;16(2-3):102-108.

[2] Chou ST, et al. Exploring the antimicrobial and antioxidant properties of Hibiscus sabdariffa extracts. J Food Sci. 2016;81(1):M181-192.

1. Pharmacokinetics & Absorption Dynamics

Myo-inositol is an isomer of inositol that serves as a constituent of membrane phospholipids and a precursor to inositol triphosphate (IP3) second messengers. In the ovaries and peripheral tissues, myo-inositol acts as the second messenger of Follicle-Stimulating Hormone (FSH) signaling and cellular glucose uptake, facilitating glucose transporter 4 (GLUT4) translocation.

2. Biological Mechanism of Action (MOA)

androgen production.

dominant Graafian follicles.

• 1. Insulin Sensitizer: Enhances peripheral and ovarian insulin sensitivity, diminishing hyperinsulinemic stimulation of theca cell
• 2. FSH Signal Transduction: Restores intra-ovarian FSH receptor sensitivity, rescuing arrested antral follicles into mature
• 3. Oocyte Nuclear Quality: Accumulates in human follicular fluid, promoting meiotic maturation and blastocyst viability.

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Ovulation Restoration: 72% of anovulatory women resumed regular ovulatory cycles
• Androgen Reduction: -52% decrease in free testosterone; marked clearance of acne
• Insulin Sensitivity: -41% reduction in HOMA-IR index without gastrointestinal distress

5. Safety & Regulatory Alignment

GRAS certified, zero teratogenic potential, FSSAI approved, globally recognized standard of care.

6. Key References (PubMed / Academic)

[1] Unfer V, et al. Effects of inositol(s) in women with PCOS: a systematic review of randomized-controlled trials. Gynecol Endocrinol. 2012;28(7):509-515.

[2] Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS. Eur Rev Med Pharmacol Sci. 2012;16(5):575-581.

1. Pharmacokinetics & Absorption Dynamics

D-Chiro-Inositol (DCI) is synthesized in the body via epimerization of myo-inositol by epimerase enzymes under insulin control. DCI acts as the intracellular messenger mediating glycogen synthesis in liver and skeletal muscles. In women with PCOS, epimerase activity in the ovaries is dysregulated; supplying the precise physiological ratio of 40:1 (Myo:DCI) restores balance without ovary toxicity.

2. Biological Mechanism of Action (MOA)

glucose disposal.

maintaining optimal 40:1 physiological equilibrium.

women.

• 1. Hepatic & Skeletal Glucose Storage: Facilitates pyruvate dehydrogenase and glycogen synthase activation, speeding up
• 2. Precise 40:1 Ratio Harmony: Avoids high-dose DCI-induced ovarian toxicity (which worsens blastocyst quality if oversupplied),
• 3. Metabolic Syndrome Protection: Lowers blood pressure, triglycerides, and cardiovascular risk markers in insulin-resistant

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Ovulation Induction: 86% spontaneous ovulation response in metabolic PCOS
• Fasting Insulin: -50% reduction in circulating hyperinsulinemic drive
• Blood Pressure: Clinically meaningful reduction in systolic/diastolic arterial pressures

5. Safety & Regulatory Alignment

GRAS certified, FSSAI approved, natural botanical extraction from carob pods.

6. Key References (PubMed / Academic)

[1] Nestler JE, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314-1320.

[2] Bizzarri M, et al. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology. Expert Opin Pharmacother. 2014;15(1):143-156.

1. Pharmacokinetics & Absorption Dynamics

CoQ10 is an indispensable electron carrier embedded within the inner mitochondrial membrane, shuttling electrons from Complex I and II to Complex III of the electron transport chain. Human oocytes contain the highest mitochondrial density of any human cell (>100,000 mitochondria per mature oocyte). CoQ10 bio-availability drops precipitously with age and oxidative stress, causing meiotic spindle breakdown.

2. Biological Mechanism of Action (MOA)

meiotic division.

aneuploidies (Down syndrome, trisomies).

• 1. ATP Powerhouse: Maximizes cellular adenosine triphosphate (ATP) production essential for chromosomal segregation during
• 2. Meiotic Spindle Integrity: Protects spindle microtubules from oxidative free-radical fragmentation, decreasing nondisjunction
• 3. Endothelial Protection: Enhances vascular perfusion to the corpus luteum and developing follicle.

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Aneuploidy Reduction: 44% reduction in chromosomal segregation errors
• Fertilization Rate: Increased from 45.1% to 67.4% (p = 0.001)
• High-Grade Embryos: 2-fold increase in morphologically superior blastocysts

5. Safety & Regulatory Alignment

Naturally synthesized in human cells, non-toxic, USP verified, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Bentov Y, et al. Coenzyme Q10 supplementation improves ovarian response in reproductive-age women. Fertil Steril. 2014;101(2):354-361.

[2] Xu Y, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women. Reprod Biol Endocrinol. 2018;16(1):29.

1. Pharmacokinetics & Absorption Dynamics

Cholecalciferol undergoes hepatic 25-hydroxylation to 25-hydroxyvitamin D [25(OH)D] and subsequent renal/tissue 1a-hydroxylation by CYP27B1 into active calcitriol [1,25(OH)2D]. Active vitamin D binds to the nuclear Vitamin D Receptor (VDR), functioning as a potent nuclear transcription factor across ovarian granulosa cells, the endometrium, and the placenta.

2. Biological Mechanism of Action (MOA)

in PCOS and preserving ovarian reserve.

adhesion and decidualization.

embryo.

• 1. Anti-Müllerian Hormone (AMH) Modulation: Modulates AMH gene transcription promoter regions, normalizing excessive AMH
• 2. Endometrial Implantation: Upregulates HOXA10 gene expression in the secretory phase endometrium, promoting blastocyst
• 3. Immune Regulation: Shifts macrophage polarization toward tolerogenic M2 states, preventing immune rejection of the early

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Implantation Receptivity: +44% higher clinical pregnancy rate in replete states
• AMH Harmonization: Significant stabilization in hyper-AMH PCOS phenotypes
• Insulin Sensitivity: 28% reduction in homeostatic fasting insulin levels

5. Safety & Regulatory Alignment

ICMR-NIN DRI 2020 calibrated, non-toxic at therapeutic dosages, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Pal L, et al. Vitamin D status relates to reproductive success in women undergoing in vitro fertilization. Fertil Steril. 2016;105(5):1302-1308.

[2] Pilz S, et al. The role of vitamin D in fertility and during pregnancy and lactation. Nutrients. 2018;10(11):1808.

1. Pharmacokinetics & Absorption Dynamics

Chromium is an essential trace element that complexes with low-molecular-weight chromium-binding substance (LMWCr or chromodulin). In chromium picolinate, picolinic acid acts as a natural lipophilic chelating agent, dramatically increasing gastrointestinal absorption compared to inorganic chromium chloride.

2. Biological Mechanism of Action (MOA)

kinase activity 8-fold upon insulin binding.

intracellular glucose uptake.

testosterone and androstenedione production.

• 1. Tyrosine Kinase Activation: Chromodulin binds to the intracellular beta-subunit of the insulin receptor, augmenting tyrosine
• 2. GLUT4 Translocation: Stimulates the movement of glucose transporter-4 vesicles to cell membranes, facilitating rapid
• 3. Reduction of Thecal Androgens: Diminishes hyperinsulinemia, eliminating the primary stimulus for excessive ovarian

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Fasting Insulin: -3.2 uIU/mL mean clinical reduction
• HOMA-IR: 32% improvement in insulin resistance score
• Lipid Profile: Significant decrease in serum triglycerides and LDL-cholesterol

5. Safety & Regulatory Alignment

GRAS certified, non-toxic trivalent form (Cr3+), ICMR DRI aligned, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Jamilian M, et al. The effects of chromium supplementation on endocrine and metabolic profiles in PCOS. J Clin Endocrinol Metab. 2016;101(7):2751-2760.

[2] Anderson RA. Chromium in the prevention and control of diabetes. Diabetes Metab. 1998;26(1):32-38.

1. Pharmacokinetics & Absorption Dynamics

Melatonin is an amphiphilic indolamine that easily crosses all biological membranes and the blood-follicle barrier. When taken orally, it achieves peak serum concentrations within 40 minutes and rapidly accumulates in human preovulatory follicular fluid at concentrations 3-fold higher than in peripheral venous blood.

2. Biological Mechanism of Action (MOA)

oocyte microenvironment.

quench free radicals in a durable cascade.

amplitude of the preovulatory luteinizing hormone surge.

• 1. Direct Free-Radical Scavenger: Directly neutralizes hydroxyl (*OH), peroxyl, and singlet oxygen radicals within the developing
• 2. Cascade Antioxidant Reaction: Each melatonin molecule produces secondary scavengers (AFMK, AMK) that continue to
• 3. Circadian LH Peak Synchronization: Stabilizes hypothalamic suprachiasmatic nucleus rhythms, optimizing the timing and

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• DNA Oxidative Damage: -60% reduction in intrafollicular 8-OHdG markers
• Fertilization Rate: Increased from 20.2% to 50.0% in compromised cohorts
• Blastocyst Yield: 2.5-fold increase in Grade-A blastocyst morphology

5. Safety & Regulatory Alignment

Physiologically bio-identical, non-habit forming at 3 mg dosage, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Tamura H, et al. Melatonin improves oocyte quality and pregnancy outcome in women with failed IVF. J Pineal Res. 2012;52(1):80-87.

[2] Espino J, et al. Impact of Melatonin on oocyte quality and human reproductive success. Antioxidants. 2019;8(8):276.

1. Pharmacokinetics & Absorption Dynamics

L-Arginine is a conditionally essential semi-proteinogenic amino acid that serves as the mandatory physiological substrate for endothelial Nitric Oxide Synthase (eNOS). Cellular conversion of L-arginine to nitric oxide (NO) and L-citrulline diffuses into vascular smooth muscle, activating soluble guanylyl cyclase (sGC) to induce robust cyclic GMP-mediated vasodilation.

2. Biological Mechanism of Action (MOA)

endometrium.

basale and spongiosum.

ovarian follicles.

• 1. Radial Uterine Vasodilation: Relaxes resistance vessels within the myometrium and spiral arterioles supplying the
• 2. Endometrial Proliferation: Reverses 'thin refractory endometrium' by delivering oxygen and micronutrients directly to the stratum
• 3. Follicular Hemodynamics: Enhances blood flow velocity to the theca interna, optimizing systemic delivery of gonadotropins to

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Endometrial Expansion: Increased from 6.2 mm to 9.1 mm (receptive threshold)
• Vascular Resistance: -42% reduction in uterine radial artery pulsatility index
• Implantation Enhancement: 3-fold elevation in embryo implantation success

5. Safety & Regulatory Alignment

GRAS certified amino acid, safe for preconception use, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Battaglia C, et al. Adjuvant L-arginine treatment for in-vitro fertilization in poor-responder patients. Hum Reprod. 1999;14(7):1690-1697.

[2] Kim JY, et al. The effect of oral L-arginine on the thickness of endometrium in IVF cycles. J Assist Reprod Genet. 2014;31(2):169-174.

1. Pharmacokinetics & Absorption Dynamics

N-Acetyl Cysteine is a stable acetylated precursor to the rate-limiting amino acid L-cysteine. Following rapid intestinal deacetylation, intracellular cysteine drives the enzymatic de novo synthesis of Reduced Glutathione (GSH), the primary endogenous antioxidant of mammalian cells. It also hydrolyzes mucin disulfide bonds, improving cervical mucus permeability.

2. Biological Mechanism of Action (MOA)

sperm-penetrable tracks.

• 1. Intracellular GSH Regeneration: Restores depleted glutathione stores in ovarian granulosa cells, combating oxidative stress.
• 2. Cervical Mucus Rheology: Cleaves mucoprotein disulfide bonds, transforming thick, impermeable cervical mucus into fluid,
• 3. Insulin-Sensitizing Synergy: Protects beta-cell insulin secretory granules, augmenting peripheral glucose disposal.

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Ovulation Induction: 52.1% success in resistant anovulatory cohorts
• Clinical Pregnancy: 2.3-fold increase over placebo control
• Cervical Receptivity: 78% improvement in post-coital cervical mucus score

5. Safety & Regulatory Alignment

Established global safety profile, non-hormonal, non-toxic, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Salehpour S, et al. N-acetylcysteine as an adjuvant to clomiphene citrate for successful induction of ovulation in PCOS. Eur J Obstet Gynecol Reprod Biol. 2012;160(2):228-231.

[2] Cheraghi E, et al. Comparing the effects of metformin and N-acetylcysteine on insulin resistance and folliculogenesis. Int J Fertil Steril. 2014;8(3):281-288.

1. Pharmacokinetics & Absorption Dynamics

Unlike inorganic sodium selenite which is poorly absorbed and rapidly excreted, organic L-selenomethionine incorporates into the structural methionine pool of body tissues. It is systematically utilized by ribosomal selenocysteine machinery to synthesize 25 unique human selenoproteins, including the crucial antioxidant enzymes Glutathione Peroxidase 1-4 (GPx) and Thioredoxin Reductase.

2. Biological Mechanism of Action (MOA)

delicate oocyte cell membranes.

active T3 necessary for ovulation.

• 1. Lipid Hydroperoxide Cleavage: GPx converts cytotoxic lipid peroxides and hydrogen peroxide into harmless water, protecting
• 2. Thyroid Hormone Deiodination: Acts as cofactor for Iodothyronine Deiodinases, ensuring conversion of prohormone T4 into
• 3. Trophoblast Invasion: Protects placental syncytiotrophoblasts against ischemia-reperfusion oxidative injury.

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Oxidative Stress Reduction: -34% reduction in plasma malondialdehyde
• Systemic hs-CRP: -38% decrease in chronic micro-inflammatory markers
• Thyroid Deiodinase Activity: Optimization of circulating free T3 levels

5. Safety & Regulatory Alignment

Natural organic form, complies with ICMR DRI 2020 upper safe limits, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Jamilian M, et al. Metabolic response to selenium supplementation in women with PCOS. Clin Endocrinol. 2015;83(6):880-886.

[2] Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-1268.

1. Pharmacokinetics & Absorption Dynamics

Natural d-alpha tocopherol is transported in circulating lipoproteins (chylomicrons, LDL, HDL) and uniquely recognized by hepatic alpha-tocopherol transfer protein (a-TTP), which distributes it preferentially to cell membranes throughout the body. It intercalates into the polyunsaturated fatty acid (PUFA) tails of ovarian and endometrial phospholipid bilayers.

2. Biological Mechanism of Action (MOA)

cascade of membrane lipid peroxidation.

and increasing uterine blood flow.

• 1. Chain-Breaking Antioxidant: Rapidly donates phenolic hydrogen to lipid peroxyl radicals (ROO*), stopping the catastrophic
• 2. Subendometrial Vasodilation: Stimulates local endothelial production of prostacyclin (PGI2), relaxing subendometrial arterioles
• 3. Telomere Protection: Shields maternal gamete DNA from oxidative guanine transversion mutations.

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Endometrial Expansion: Increased from 5.8 mm to 8.4 mm
• Vascular Perfusion: 72% of patients showed significant increase in blood flow index
• Cellular Protection: Complete cessation of free-radical chain propagation in oocyte lipids

5. Safety & Regulatory Alignment

Natural isomer, safe and bio-identical, ICMR DRI 2020 aligned, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Cicek N, et al. Vitamin E treatment improves endometrial response in patients with unexplained thin endometrium. Fertil Steril. 2012;98(3):S242-243.

[2] Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med. 2007;43(1):4-15.

1. Pharmacokinetics & Absorption Dynamics

Black cohosh contains triterpene glycosides and phenolic acids (isoferulic acid). Historically thought to be estrogenic, rigorous modern pharmacology proves it acts centrally as a selective neuroendocrine modulator without binding to Estrogen Receptor-Alpha (ERa). It crosses the blood-brain barrier to modulate hypothalamic serotonin (5-HT) and opioid receptors.

2. Biological Mechanism of Action (MOA)

the narrowed thermoneutral zone and terminating abrupt vasomotor hot flashes.

relief for women with hormone contraindications.

swings, and insomnia.

• 1. Central Thermoregulatory Stabilization: Binds to 5-HT1A and 5-HT7 serotonin receptors in the preoptic hypothalamus, widening
• 2. Non-Estrogenic Safety: Does not stimulate uterine endometrial hyperplasia or breast epithelial cell proliferation, providing safe
• 3. Psychotropic Harmony: Interacts with central GABAergic and mu-opioid pathways to alleviate menopausal anxiety, mood

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Kupperman Menopausal Index: -80% drop in overall climacteric symptom severity
• Hot Flash Frequency: -74% reduction in vasomotor episodes
• Endometrial Safety: Zero endometrial hyperplasia or oncogenic stimulation (p < 0.0001)

5. Safety & Regulatory Alignment

Monographed in German Commission E, USP-NF compliant, non-estrogenic, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Wuttke W, et al. The non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (Cimicifuga or Actaea racemosa). Maturitas. 2003;44(Suppl 1):S67-S77.

[2] Schellenberg R, et al. Dose-dependent effects of the Cimicifuga racemosa extract Ze 450 in menopausal women. Gynecol Endocrinol. 2012;28(3):217-225.

1. Pharmacokinetics & Absorption Dynamics

Shatavari root is rich in steroidal saponins termed shatavarins (I-IV), sarsasapogenin, and isoflavones. Following enzymatic hydrolysis by commensal gut microbiota into aglycones, these bioactive phytosterols selectively bind with higher affinity to Estrogen Receptor-Beta (ERb) than Estrogen Receptor-Alpha (ERa).

2. Biological Mechanism of Action (MOA)

system, and vaginal epithelium without oncogenic ERa breast stimulation.

and reducing excess cortisol.

dyspareunia and atrophic vaginitis.

• 1. Selective ERb Agonism: Exerts protective, tissue-selective estrogenic balance in the cardiovascular system, central nervous
• 2. Adrenal Cortical Support: Modulates the hypothalamic-pituitary-adrenal (HPA) axis, tempering menopausal adrenal exhaustion
• 3. Urogenital Mucosal Rejuvenation: Stimulates natural mucosal fluid secretion and urothelial glycogen deposition, reversing

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Vaginal Atrophy Relief: 73% reduction in dryness and dyspareunia
• HPA Axis Balance: 24% reduction in elevated nocturnal cortisol levels
• ERb Selectivity: Pure protective beta-receptor pathway activation

5. Safety & Regulatory Alignment

Ayurvedic Pharmacopoeia of India (API) monographed, WHO-GMP certified, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Pandey AK, et al. Impact of stress on female reproductive health: Protective role of Asparagus racemosus. Biomed Pharmacother. 2018;103:46-59.

[2] Alok S, et al. Plant profile, phytochemistry and pharmacology of Asparagus racemosus (Shatavari): A review. Asian Pac J Trop Dis. 2013;3(3):242-251.

1. Pharmacokinetics & Absorption Dynamics

Red clover contains four distinct therapeutic isoflavones: biochanin A, formononetin, genistein, and daidzein. In the intestine, hepatic and colonic enzymes demethylate biochanin A and formononetin into genistein and daidzein, which are subsequently conjugated into circulating glucuronides that exhibit remarkable structural mimicry of 17b-estradiol.

2. Biological Mechanism of Action (MOA)

estrogenic modulation.

menopausal vascular stiffness.

mineral density.

• 1. Quad-Isoflavone Synergy: Provides 4 distinct isoflavones compared to soy which only contains two, delivering comprehensive
• 2. Cardiovascular Compliance: Stimulates endothelial nitric oxide synthase, preserving arterial elasticity and preventing
• 3. Bone Remodeling Balance: Suppresses osteoclast bone resorption by downregulating RANKL, maintaining skeletal bone

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Hot Flash Abatement: -62% reduction in confirmed daily episodes
• Night Sweats: -68% decrease in nocturnal diaphoresis severity
• Endometrial Safety: Zero endometrial proliferative stimulation (biopsy confirmed)

5. Safety & Regulatory Alignment

Well-documented European and US clinical safety, FSSAI approved botanical extract.

6. Key References (PubMed / Academic)

[1] Hidalgo LA, et al. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women. Maturitas. 2005;50(4):272-279.

[2] Ghazanfarpour M, et al. Red clover for treatment of hot flashes and menopausal symptoms: a systematic review and meta-analysis. Climacteric. 2015;18(6):783-792.

1. Pharmacokinetics & Absorption Dynamics

Evening Primrose Oil (EPO) provides pre-formed Gamma-Linolenic Acid (18:3n-6, GLA), directly bypassing the rate-limiting Delta-6-Desaturase (D6D) enzyme. D6D activity is notoriously suppressed by stress, insulin resistance, elevated prolactin, and aging. Ingested GLA is rapidly elongated into Dihomo-Gamma-Linolenic Acid (DGLA).

2. Biological Mechanism of Action (MOA)

anti-inflammatory and vasodilating eicosanoid that competitively inhibits inflammatory 2-series prostaglandins (PGE2, PGF2a).

extinguishing agonizing cyclic mastalgia.

and restoring dry menopausal skin.

• 1. Anti-Inflammatory PGE1 Generation: DGLA is transformed by cyclooxygenase into Prostaglandin E1 (PGE1), a potent
• 2. Breast Tissue Prolactin Desensitization: Blunts hyper-responsiveness of breast ductal lobules to circulating prolactin,
• 3. Skin Barrier Restoration: Incorporates into epidermal stratum corneum ceramides, reducing trans-epidermal water loss (TEWL)

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Mastalgia Relief: 78% reduction in cyclic breast pain severity
• Delta-6-Desaturase Bypass: 100% efficient direct delivery of biological DGLA
• Epidermal Moisture: 31% improvement in skin hydration and barrier elasticity

5. Safety & Regulatory Alignment

Cold-pressed pure oil, non-GMO, chemical-solvent free, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Farzaneh F, et al. The effect of evening primrose oil on cyclical mastalgia and PMS: a double-blind, randomized, placebo-controlled trial. Arch Gynecol Obstet. 2013;288(5):1075-1079.

[2] Mahboubi M. Evening Primrose (Oenothera biennis) Oil in management of menopausal and premenstrual symptoms. Crit Rev Food Sci Nutr. 2019;59(1):145-159.

1. Pharmacokinetics & Absorption Dynamics

Unlike standard pyridoxine hydrochloride which requires hepatic phosphorylation and oxidation via FMN-dependent oxidase enzymes, Pyridoxal-5-Phosphate (P-5-P) is the direct, biologically active coenzyme form. It directly binds to apoenzymes across the central nervous system without demanding hepatic conversion.

2. Biological Mechanism of Action (MOA)

rate-limiting decarboxylation of 5-HTP into Serotonin and L-DOPA into Dopamine.

calming irritability and panic.

bloating.

• 1. Serotonin & Dopamine Biosynthesis: Obligate cofactor for Aromatic L-Amino Acid Decarboxylase (AADC), catalyzing the
• 2. GABA Synthesis: Serves as cofactor for Glutamate Decarboxylase, converting excitatory glutamate into inhibitory GABA,
• 3. Renal Fluid Regulation: Regulates the cellular sodium-potassium pump, counteracting aldosterone-mediated fluid retention and

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Neuro-Affective Response: 2.3-fold higher efficacy over placebo in emotional stabilization
• Somatic Bloating: 65% reduction in self-reported water retention and breast heaviness
• Enzymatic Bioavailability: 100% active coenzyme delivery bypassing liver bottlenecks

5. Safety & Regulatory Alignment

Active non-toxic coenzyme form, conforms to ICMR DRI guidelines, FSSAI approved.

6. Key References (PubMed / Academic)

[1] Wyatt KM, et al. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999;318(7195):1375-1381.

[2] Sharma P, et al. Role of active pyridoxal-5-phosphate in premenstrual mood disorders. J Clin Diagn Res. 2007;1(6):534-541.

1. Pharmacokinetics & Absorption Dynamics

Ashwagandha contains steroidal lactones known as withanolides (withaferin A, withanolide A, withanone). KSM-66® uses a proprietary milk-pretreated water extraction preserving the full natural spectrum of the root. Lipophilic withanolides penetrate the central nervous system, binding to GABA-A receptors and modulating neuroendocrine HPA axis feedback loops.

2. Biological Mechanism of Action (MOA)

cortisol secretion.

muscle breakdown.

restorative sleep.

• 1. HPA Axis Downregulation: Attenuates adrenocorticotropic hormone (ACTH) signaling at the adrenal cortex, reducing excess
• 2. Anabolic Muscle Protein Synthesis: Promotes muscular nitrogen retention and reduces exercise-induced Creatine Kinase (CK)
• 3. Neuro-GABA Mimetic Action: Enhances calming alpha-wave brain rhythm activity, optimizing deep stage-3 non-REM

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Cortisol Reduction: -27.9% reduction in circulating serum cortisol
• Stress Scale Abatement: -44.0% reduction in Perceived Stress Scale (PSS)
• Recovery Acceleration: 38% decrease in post-exercise muscle soreness

5. Safety & Regulatory Alignment

USP-verified extract, GRAS affirmed, WHO-GMP certified, FSSAI approved adaptogen.

6. Key References (PubMed / Academic)

[1] Chandrasekhar K, et al. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root. Indian J Psychol Med. 2012;34(3):255-262.

[2] Choudhary B, et al. Efficacy of Ashwagandha (Withania somnifera) in improving cardiorespiratory endurance in healthy athletic adults. J Diet Suppl. 2015;14(6):599-612.

1. Pharmacokinetics & Absorption Dynamics

Curcuminoids are lipophilic diferuloylmethane polyphenols extracted from turmeric rhizomes. Modern co-formulations with piperine or phospholipid carriers enhance oral absorption 20-fold. In circulation, curcumin binds to serum albumin, transporting throughout musculoskeletal and connective tissue matrices where it accumulates in inflamed tissues.

2. Biological Mechanism of Action (MOA)

from entering the cell nucleus to trigger inflammatory gene expression.

gastric protective COX-1 prostaglandins.

Interleukin-6 (IL-6).

• 1. NF-kB Nuclear Translocation Arrest: Prevents phosphorylation and degradation of IkB, blocking nuclear factor kappa B (NF-kB)
• 2. Dual COX-2 & 5-LOX Inhibition: Downregulates inflammatory cyclooxygenase-2 and lipoxygenase enzymes without damaging
• 3. Cytokine Storm Suppression: Dramatically reduces circulating levels of Tumor Necrosis Factor-Alpha (TNF-a), IL-1b, and

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Systemic hs-CRP: -58% reduction in chronic systemic inflammation
• Inflammatory Cytokines: Statistically significant suppression of TNF-a and IL-6
• Gastric Safety: Zero gastrointestinal adverse events or ulcerations

5. Safety & Regulatory Alignment

GRAS certified, FDA NDI listed, WHO-GMP certified, FSSAI approved botanical.

6. Key References (PubMed / Academic)

[1] Panahi Y, et al. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial. Phytother Res. 2015;29(11):1723-1729.

[2] Daily JW, et al. Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis. J Med Food. 2016;19(8):717-729.

1. Pharmacokinetics & Absorption Dynamics

Unlike intact whole proteins requiring extensive gastric protease breakdown, enzymatically pre-hydrolyzed peptides bypass complex digestion. Di- and tri-peptides are actively absorbed across intestinal enterocytes via high-capacity PEPT1 transporters far more rapidly than free amino acids, producing an immediate postprandial hyperaminoacidemia within 20 to 30 minutes.

2. Biological Mechanism of Action (MOA)

1 (mTORC1), switching on muscle protein synthesis (MPS).

women.

enteroendocrine L-cells, promoting prolonged satiety.

• 1. mTORC1 Molecular Activation: Rapid transient peak in plasma L-leucine triggers the mammalian target of rapamycin complex
• 2. Nitrogen Balance Recovery: Reverses catabolic muscle wasting, postpartum tissue fatigue, and age-related sarcopenia in
• 3. Satiety Neuropeptide Secretion: Stimulates the release of glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) from

3. Human Clinical Trials & Evidence Synthesis

4. Quantitative Clinical Endpoints & Tolerability

• Muscle Protein Synthesis: +40% higher acute fractional synthetic rate (FSR)
• Absorption Velocity: Peak plasma amino acid concentration (Cmax) reached within 25 min
• Satiety Index: Proven elevation in circulating GLP-1 and CCK peptides

5. Safety & Regulatory Alignment

Clean label, low lactose/sugar-free, FSSAI approved, WHO-GMP certified.

6. Key References (PubMed / Academic)

[1] Phillips SM. The impact of protein quality on the promotion of resistance exercise-induced changes in muscle mass. Sports Med. 2016;46(Suppl 1):19-27.

[2] Devries MC, Phillips SM. Supplemental protein in support of muscle mass and health: advantage whey. J Food Sci. 2015;80(Suppl 1):A8-A15.